Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

October 31, 2009

Conditions
Breast CancerColorectal CancerHead and Neck CancerKidney CancerLung CancerOvarian CancerPancreatic CancerProstate CancerSarcoma
Interventions
DRUG

bortezomib

Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m\^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.

DRUG

gemcitabine hydrochloride

Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m\^2) on day 1 and day 8 of a 21 day cycle.

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00620295 - Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter